Upstream Bio Appoints Allison Ambrose as General Counsel
17 déc. 2024 08h00 HE
|
Upstream Bio
Upstream appoints Allison Ambrose as General Counsel
Upstream Bio Announces Addition to Russell 2000® Index
16 déc. 2024 08h00 HE
|
Upstream Bio
Upstream Bio (Nasdaq:UPB) to be added to Russell 2000® index effective at the open of the U.S. equities market on Monday, December 23.
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
21 nov. 2024 08h00 HE
|
Upstream Bio
Upstream Bio CEO to participate in fireside chat at Piper Sandler
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
07 nov. 2024 07h00 HE
|
Upstream Bio
Upstream reports third quarter 2024 financial results and recent corporate achievements
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
15 oct. 2024 16h15 HE
|
Upstream Bio
Upstream closes $293 million upsized IPO including full exercise of underwriters’ option to purchase additional shares
Upstream Bio Announces Pricing of Upsized Initial Public Offering
10 oct. 2024 19h35 HE
|
Upstream Bio
Upstream Bio announces pricing of upsized initial public offering
AB Science a reçu les premières autorisations règlementaires pour initier une étude clinique confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer
10 oct. 2022 12h04 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A REÇU LES PREMIÈRES AUTORISATIONS RÈGLEMENTAIRES POUR INITIER UNE ÉTUDE CLINIQUE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA MALADIE...
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
10 oct. 2022 12h04 HE
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th 2022, 6pm...
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
10 nov. 2020 16h05 HE
|
Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress
08 sept. 2020 02h44 HE
|
AB Science
Paris, 08 September 2020, 7.30am AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress Abstract...